The Drug Regulatory Authority stopped plasma therapy of code 19

The Drug Regulatory Authority stopped plasma therapy of code 19

KARACHI: The Drug Regulatory Authority (DRA) has unannouncedly stopped plasma therapy treatment for coronavirus outbreaks across the country and has not released the results of clinical trials of plasma therapy even after a lapse of one and a half months.


People who voluntarily donate plasma with their blood in the national spirit want to know how much their donations have benefited Code 19 patients. 


For the first time in Pakistan, the Drug Regulatory Authority allowed NIBD to conduct a clinical trial of plasma therapy in April to save the lives of Code 19 patients.


Clinicals across the country lasted for two months. The clinical trial was also monitored directly from the Presidency. 


In August, the clinical trial of plasma therapy was completed and its report was submitted to the Drug Regulatory Authority, after which the Drug Regulatory Authority did not allow further trials or clinical trials. 


Informed the public about the results of the trial. On April 9, 2020, the Drug Regulatory Authority of Pakistan authorized a clinical trial of plasma therapy for the treatment of COD 19 patients.


The clinical trial includes NIBD chief Dr. Tahir Shamsi, Lahore University professor Dr. Javed Ikram, Liaquat Medical University Jamshoro professor Beka Ram and other experts.


It should be noted that the US Food and Drug Regulatory Authority had on August 23, 2020, approved and approved the treatment of cod patients through plasma therapy, after which plasma therapy has been given to more than one lakh corona patients all over the world including Pakistan. 

The Drug Regulatory Authority stopped plasma therapy of code 19 The Drug Regulatory Authority stopped plasma therapy of code 19 Reviewed by Muhammad Akram on October 09, 2020 Rating: 5

No comments:

Powered by Blogger.